Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

virin in combination with:

  • Janssen's non-nucleoside inhibitor TMC647055 and ritonavir in treatment-naïve genotype 1a and 1b HCV patients;
  • Gilead Sciences, Inc.'s nucleotide inhibitor sofosbuvir (GS-7977) in treatment-naïve and previous null-responder genotype 1 HCV patients; and
  • Bristol- Myers Squibb 's NS5A replication complex inhibitor daclatasvir in treatment-naive and previous null-responder genotype 1 HCV patients.

In addition, Janssen Pharmaceuticals, Inc. has entered into a non-exclusive collaboration with Vertex Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen of simeprevir and Vertex's investigational nucleotide analogue polymerase inhibitor VX-135 for the treatment of HCV. As a first step, Janssen Pharmaceuticals, Inc. is conducting a drug-drug interaction (DDI) study with simeprevir and VX-135. Janssen Pharmaceuticals, Inc. also has plans to initiate a Phase 2 trial of an investigational interferon-free regimen with simeprevir, TMC647055 and Idenix's IDX719, a once-daily, pan-genotypic NS5A inhibitor, with and without ribavirin.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Janssen R&D Ireland
At Janssen, we are dedicated to addres
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... 4, 2011 A team of scientists at Tufts ... single-cell levels designed to detect breast cancer earlier, and ... Innovator Award from the Department of Defense Breast Cancer ... Ph.D. The Innovator Awards provide "individuals who ...
...   Research led by St. Jude Children,s Research Hospital scientists ... that are the workhorses of cells and, in the ... The discovery involves a chemical known as ... proteins have this chemical added to the amino acid ...
Cached Medicine Technology:Fighting Breast Cancer Early, One Cell At A Time 2Fighting Breast Cancer Early, One Cell At A Time 3Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... independent freestanding emergency rooms in the United States, named ... its new Missouri City-Lakes facility. , “We are ... as facility medical director of our new Missouri City-Lakes ... of First Choice Emergency Room. , Dr. Harrison ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in the ... for its maternity wedding outfits. Now, all the company’s ... wedding dresses on its website. , 9Lover.com ... The company’s development manager believes the cheap maternity wedding ... current special offer will last until September 29, 2014. ...
(Date:9/17/2014)... A ball gown is the most ... a full-skirted gown reaching the floor, made of luxurious ... special occasion gown manufacturer and retailer, has delightedly unveiled ... ball gowns are offered at discounted rates. , Most ... Such gowns are typically worn with a stole (a ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 The National ... the Match , a comprehensive analysis of the relationship ... a preferred specialty. The new edition is based ... by specialty for U.S. allopathic medical school senior students ... to be able to provide this new edition of ...
(Date:9/17/2014)... Battle Creek, MI (PRWEB) September 17, 2014 ... Recovery , an open-ended drug and alcohol treatment program ... gives them a solid foundation in recovery they can ... and depression. , “About 20% of Americans who are ... or both,” commented A Forever Recovery’s CEO Per ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3
... to lack a particular protein in the brain have ... they say, for exploring the hereditary causes of deafness ... provides an entry point for gaining new insight into ... the protein, says the team, led by scientists at ...
... ATSI ) is looking forward to its ... of Thoracic Surgeons (STS). The event runs January,28-30, ... one of the year,s,key gatherings of cardiovascular surgeons ... ), ATS Medical continues to broaden its ...
... Rochester,Medical Corporation (Nasdaq: ROCM ) will announce quarterly ... The Company will then,hold a quarterly conference call to ... p.m. central standard time (5:00 p.m. eastern time)., ... be accessed at,Rochester Medical,s website at http://www.rocm.com . ...
... PRINCETON, N.J., Jan. 24 The final ... Care Resources,provides a thorough and candid explanation of ... short on delivering solutions to address,the healthcare system,s ... consensus of the New Jersey Hospital Association, the,state,s ...
... Personalizing ones nutrition for maximum health benefits is becoming ... help health professions learn more about this trend at ... Nutrition" is the theme for the 35th annual Texas ... The event, at the Rudder Tower, is from 8 ...
... on healthy living, healthy aging, healthy ... communities, ... million investment in three initiatives that will help,Silicon Valley become the healthiest ... strides in achieving the goals,of healthy living, healthy aging, and healthy communities ...
Cached Medicine News:Health News:Deafness and seizures result when mysterious protein deleted in mice 2Health News:Deafness and seizures result when mysterious protein deleted in mice 3Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 2Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 3Health News:Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008 2Health News:NJHA: State Report Provides Thorough Examination of Hospital Fiscal Woes 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 3
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... is indicated for the treatment of ... as telangiectasia, rosacea, spider angiomas, cherry ... papulosis nigra and keratoses. Patented ... selection of handpieces maximizes versatility, compact ...
... handpieces, used for endophotocoagulation ... with uncompromised laser treatment ... EndoProbe handpieces are compatible ... green (532 nm), OcuLight ...
Medicine Products: